8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________
FORM 8-K
_________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 6, 2015
_________________________________
Global Blood Therapeutics, Inc.
(Exact name of Registrant as Specified in its Charter)
_________________________________
|
| | | | |
|
| | | | |
Delaware | | 001-37539 | | 27-4825712 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
400 East Jamie Court, Suite 101
South San Francisco, CA 94080
(Address of Principal Executive Offices) (Zip Code)
(650) 741-7700
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
| |
¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On December 6, 2015, Global Blood Therapeutics, Inc. issued a press release titled, “Global Blood Therapeutics Announces Positive Phase 1/2 Data Supporting Development of GBT440 as a Potentially Disease-Modifying Therapy for Sickle Cell Disease” (the “Press Release”). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
| |
Exhibit No. | Description |
99.1 | Press Release dated December 6, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | |
| GLOBAL BLOOD THERAPEUTICS, INC. |
| | |
Date: December 7, 2015 | By: | /s/ John Schembri |
| Name: | John Schembri |
| Title: | Vice President, Finance and Administration (Principal Financial and Accounting Officer) |
EXHIBIT INDEX
|
| |
Exhibit No. | Description |
99.1 | Press Release dated December 6, 2015. |